Finance

Lists
CGEM:NASDAQ
Cullinan Therapeutics Inc
14,92 US$
+0,20%
(+0,030) 1D
14,92 US$
0,00% (0,00)
After hours
Closed: 22 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGEM...
Open
14,82 US$
High
15,32 US$
Low
14,64 US$
Mkt. cap
960,17 მლნ.
Avg. vol.
1,17 მლნ.
Volume
392,65 ათ.
52-wk high
23,19 US$
52-wk low
6,75 US$
EPS
-3,41 US$
Beta
-0,05
Shares outstanding
64,36 მლნ.
No. of employees
109
Open
14,82 US$
High
15,32 US$
Low
14,64 US$
Mkt. cap
960,17 მლნ.
Avg. vol.
1,17 მლნ.
Volume
392,65 ათ.
52-wk high
23,19 US$
52-wk low
6,75 US$
EPS
-3,41 US$
Beta
-0,05
Shares outstanding
64,36 მლნ.
No. of employees
109
News stories
From web sources and news partners
About Cullinan Therapeutics Inc
CEO-
Employees109
Founded2016
Headquarters-
Sector-
Analyst ratings
Based on 12 analysts giving stock ratings to CGEM in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for CGEM in the last 3 months.
Highest
Current 14,92 US$
47,00 US$ (+215,01%)
Average
35,70 US$ (+139,28%)
Lowest
27,00 US$ (+80,97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Julian Harrison
BTIG
Buy
Reiterated
40,00 US$
+168,1%
10/19/2026
Robert Driscoll
Wedbush
Buy
Maintained
42,00 US$
+181,5%
10/07/2026
Samantha Semenkow
Citi
Buy
Maintained
33,00 US$
+121,2%
10/06/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
10/02/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
35,00 US$
+134,6%
10/02/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
09/24/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
39,00 US$
+161,4%
09/16/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
30,00 US$
+101,1%
09/15/2026
Boris Peaker
JonesTrading
Buy
Maintained
36,00 US$
+141,3%
09/14/2026
David Dai
UBS
Buy
Maintained
27,00 US$
+81%
08/17/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
28,00 US$
+87,7%
08/13/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
47,00 US$
+215%
08/14/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
06/10/2026
Soumit Roy
JonesTrading
Buy
Maintained
36,00 US$
+141,3%
04/06/2026
Bradley Canino
Guggenheim
Buy
Reiterated
30,00 US$
+101,1%
03/10/2026
Last report
6 აგვ. 2026
Fiscal period
Q2 2026
-0,81 US$ / -0,85 US$
+4,85%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
41,97 მლნ.
42,94 მლნ.
42,12 მლნ.
44,44 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,63 მლნ.
12,31 მლნ.
11,57 მლნ.
12,82 მლნ.
Operating expense
55,60 მლნ.
55,26 მლნ.
53,70 მლნ.
57,25 მლნ.
Total operating expenses
55,60 მლნ.
55,26 მლნ.
53,70 მლნ.
57,25 მლნ.
Operating income
-55,60 მლნ.
-55,26 მლნ.
-53,70 მლნ.
-57,25 მლნ.
Other non operating income
-108,00 ათ.
-69,00 ათ.
-62,00 ათ.
-98,00 ათ.
EBT including unusual items
-50,61 მლნ.
-50,71 მლნ.
-49,66 მლნ.
-53,70 მლნ.
EBT excluding unusual items
-50,61 მლნ.
-50,71 მლნ.
-49,66 მლნ.
-53,70 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-50,61 მლნ.
-50,71 მლნ.
-49,66 მლნ.
-53,70 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,77
-0,77
-0,75
-0,81
Interest and investment income
5,09 მლნ.
4,62 მლნ.
4,10 მლნ.
3,65 მლნ.
Interest expense
-
-
-
-
Net interest expenses
5,09 მლნ.
4,62 მლნ.
4,10 მლნ.
3,65 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-55,52 მლნ.
-55,18 მლნ.
-53,62 მლნ.
-57,18 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები